Global Stem Cells Group Subsidiary Stem Cell Center Network to open new facility in Puerto Rico
MIAMI, Jan. 15, 2018—Global Stem Cells Group (GSCG) subsidiary Stem Cell Center Network, the world’s largest collective support and advisory network of regenerative medicine clinics and physicians, has announced the opening a new facility in San Jose, Puerto Rico in January 2018.
Stem Cell Center Puerto Rico will provide stem cell treatments for a variety of conditions, including osteoarthritis, erectile dysfunction, and urinary incontinence. Adimarket, also a subsidiary of GSCG, will provide Stem Cell Center Puerto Rico with state-of-the-art products and technology, such as the Integrated Stem Cell Workstation.
Global Stem Cells Group CEO Benito Novas named Juan Colon, M.D. to head Stem Cell Center Puerto Rico as medical director. Colon is a urologist who has spent the past year working to help prostate cancer patients. He earned his medical degree from Recinto de Ciencias Médicas in San Juan and trained in the latest regenerative medicine protocols in December 2017 at Stem Cell Center San Jose, Costa Rica.
The Stem Cell Center Network has aggressively launched and rapidly expanded new fellowship programs, events, and other regenerative medicine events over the past five years and currently has members practicing in 25 countries.
The new San Juan center will treat patients with a variety of degenerative conditions with emphasis on osteoarthritis, according to Novas.
For more information, visit the Stem Cell Center Network website, the Global Stem Cells Group website, email info@stemcellsgroup.com, or call +1305 560 5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
About Stem Cell Center Network:
Stem Cell Center Network, a division of Global Stem Cells Group, is an international network of medical practitioners dedicated to bringing stem cell therapies to patients worldwide.
Network physicians are experts in their fields and believe that stem cell treatments are to the future of medicine. Each Network physician is dedicated to providing the best treatments and contributing to the global store of regenerative medicine knowledge and research.
About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.
Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.
- Published in Press Releases
ISSCA to Conduct Regenerative Medicine Training in Mexico City Feb.9-10, 2018
ISSCA will conduct the next regenerative medicine certification training course in Mexico City, Feb. 9-10, 2018. The two-day course focuses on harvesting adipose and bone marrow stem cells from patients in a clinical environment.
MIAMI, Jan. 15, 2018—The International Society for Stem Cell Application (ISSCA) announced plans to hold its next regenerative medicine certification training course in Mexico City, Feb. 9 – 10, 2018.
The two-day, hands-on training course will focus on harvesting adipose and bone marrow stem cells from patients in a clinical environment. Qualified physicians learn skills that can be used to treat patients in their practices, and for career advancement. The course provides participating physicians with training in stem cell applications to treat a variety of conditions.
Participating physicians will also receive access to the online stem cell training course to review all content and procedures introduced in the 2-day clinical training course, patient forms and guidelines, procedure informed consent forms, didactic lectures, training booklets, and more.
ISSCA’s stem cell certification course offers hands-on, personalized training in harvesting stem cells from a live patient. ISSCA has trained more than 2,000 physicians worldwide. The course is only available to eight physicians per training, so it is important to sign up early to reserve a seat.
The ISSCA regenerative medicine training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells.
Stem cell therapies continue to revolutionize the healthcare industry and help improve the quality of life for patients.
To learn more about the ISSCA certification training course and register to participate, visit the Stem Cell Training Course website, email info@stemcellsgroup.com, or call 305-560-5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
- Published in Press Releases
ISSCA Announces Launch of the First Bilingual (English and Spanish) Regenerative Medicine Newsletter
ISSCA has announced plans to launch the first bilingual (English and Spanish) regenerative medicine newsletter.
MIAMI, Jan. 15, 2018—The International Society for Stem Cell Application (ISSCA) will launch the first bilingual (English and Spanish) regenerative medicine newsletter January 23, 2018. The monthly newsletter will be available for free to email subscribers and shared through ISSCA social media channels.
The newsletter will include three sections:
- Regenerative Medicine Business News
- Regenerative Medicine Research and clinical applications
- Upcoming Regenerative Medicine Training
Regenerative Medicine Business News will provide the latest updates on policies, legislative, regulatory and reimbursement initiatives to support research and development of regenerative medicine products, and business development and investor information on opportunities in the fast-growing stem cell and regenerative medicine market.
Regenerative Medicine Research and clinical applications will follow the latest findings on regenerative medicine research and development—from tissue engineering to cell therapies, and the different challenges involved in live tissue handling and manufacturing. In addition, the newsletter will include information on the latest clinical applications of regenerative medicine therapies.
The newsletter will also include schedules and registration information on upcoming regenerative medicine training and certification courses, along with registration information.
To subscribe to ISSCA’s newsletter, send an email request with your contact information to info@stemcellsgroup.com.
To learn more, visit the ISSCA website, email info@stemcellsgroup.com, or call 305-560-5337.
About ISSCA:
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
- Published in Press Releases
ISSCA Announces Five-Year Sponsorship of XXVI Jornadas Mediteraneas – Mediterranean Days of Therapeutic Confrontations in Medicine and Cosmetic Surgery
ISSCA has announced its sponsorship of XXVI Jornadas Mediteraneas – Mediterranean Days of Therapeutic Confrontations in Medicine and Cosmetic Surgery to be held in Barcelona, Spain May 11 – 13, 2018. ISSCA has committed to sponsoring the event for five consecutive years.
MIAMI, Jan. 15, 2018—The International Society for Stem Cell Application (ISSCA) has announced its sponsorship of XXVI Jornadas Mediteraneas -Mediterranean Days of Therapeutic Confrontations in Medicine and Cosmetic Surgery in Barcelona, Spain May 11 – 13, 2018. ISSCA has committed to sponsoring Jornadas Mediteraneas for five consecutive years.
Global Stem Cells Group CEO and medical marketing expert Benito Novas will launch his new book, “Digital Marketing in Your Aesthetic Clinic” in Europe during the event. He will also speak about the latest digital marketing strategies critical to physicians looking to grow their practices.
Additionally, Alfredo Hoyos,M.D., world-renowned plastic surgeon and Global Stem Cell Group’s chief scientific officer (CSO) will speak about utilizing stem cells to obtain better results in aesthetic surgery procedures.
The event, one of the most influential European medical conferences, will focus on topics such as regenerative medicine and stem cell therapies, skin aging, body rejuvenation and remodeling, and 21st Century tools for professional practices to capture and retain new patients. ISSCA will host two master regenerative medicine certification training classes during the conference. The conference will be held at Hotel Meliá Sitges in Barcelona. –more— To learn more about XXVI Jornadas Mediteraneas and register to attend, visit the Stem Cell Conference website, email mailto:info@stemcellsgroup.com, or call 305-560-5337.
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.
About ISSCA:
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally. Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
###
- Published in Press Releases
Global Stem Cells Group to Hold Fifth Annual South American Regenerative Medicine Symposium in Buenos Aires, Argentina Aug. 23-25, 2018
MIAMI, Jan. 15, 2018 – Global Stem Cells Group, a world leader in stem cell and regenerative medicine, will host its South American Regenerative Medicine Symposium August 23, 24, and 25th in Buenos Aires, Argentina. This will be GSCG’s fifth consecutive year hosting the symposium.
The main topic for the 2018 event is “Next Generation Medicine: Adult Stem Cells.”
Universidad de Buenos Aires
According to Benito Novas, Global Stem Cells Group CEO, the symposium will showcase advances in adult stem cell research and therapies.
“This year’s symposium will highlight the strides stem cell research has made in adult stem cell applications,” Novas says. “
Since 2014, Global Stem Cells Group worked with some of the most prestigious regenerative medicine practitioners in South America as it focuses on growing its services throughout the global community. Stem cell therapies continue to revolutionize the healthcare industry while offering new hope for sufferers of chronic, debilitating conditions.
To learn more about the Fifth Annual South American Regenerative Medicine Symposium visit the Stem Cell Conference website, email info@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
- Published in Press Releases
Why Do We Side With Stem-Cell Therapy?
PRP and Stem Cell Therapy still have a ways to go before becoming mainstream medical practices. However, we at Adimarket are proud to be part of this growing trend. We fervently believe in the future of stem cell therapies because we trust that they offer an alternative to otherwise invasive and unnecessary medical procedures.
If we listed every single scientific reason showing the benefits of stem cell therapy, we would be writing a book. To keep it concise, we have decided to highlight three main reasons why we support this therapy and sell equipment for it.
1. It’s Been Around for a While
Stem cell therapy is neither a new nor an untested invention. This therapy has been used for decades in various procedures, such as bone marrow transplants for leukemia patients. The main issue is that stem cell therapy is not widely known.
This therapy has benefited people suffering from leukemia and other diseases like lymphoma for decades, primarily through bone marrow transplants. The safety and minimal risk of rejection, as stem cells are the body’s own, make this therapy a viable option. If they can be used to treat these conditions, there is likely much more they can do.
2. It’s Not Really Invasive
While invasive procedures will probably never be entirely obsolete (e.g., bone fractures or tooth extractions), not all invasive surgeries are necessary.
At Adimarket, we love stem cell therapy because it is minimally invasive. Instead of requiring incisions and stitches, the most a patient needs is a needle poke to extract stem cells and another to inject them into the treatment area. This reduces the risk of infection and other complications, such as scarring.
3. It Works to Improve Healing
The final reason we promote stem cell therapy is that it allows the body to heal naturally. This means that the treatment addresses the underlying problem rather than just focusing on symptom management.
We hope this approach helps patients receive better and more effective treatment, addressing the entire issue instead of just the symptoms. While stem cell therapy might not be the best choice for every case, it is similar to any other medical procedure. Not all treatments require medication and surgery.
Why Do We Side With Stem-Cell Therapy?
If you seek better and more efficient ways of treating injuries and various diseases, Adimarket is the place to go. We provide the latest and greatest technology and equipment related to PRP and stem cell therapy, helping you find better treatments for your patients.
Stem cell therapy can be highly beneficial not only for treating patients but also for increasing your revenue. Incorporating stem cell therapy may very well be the best thing you can do for your practice.
- Published in Corporate News / Blog
Can Hip Replacements Be Obsolete Through The Use Of Stem Cell Therapy?
As more and more doctors train to be proficient in stem cell therapy, many seek to increase their revenues and expand their practices. At Adimarket, we aim to fulfill the needs of doctors and help their patients in the most efficient way possible. However, we have other goals as well. We hope that one day, PRP and stem cell therapies will replace certain medical procedures, making them more effective and convenient. One such procedure we hope to eliminate is hip replacements.
Natural Tissue Regeneration in Orthopedics
Natural tissue regeneration has been a focus for many scientists for years, particularly in orthopedics, the study of bones and muscles. Utilizing a patient’s stem cells to regrow or replace cartilage can be a godsend for treating conditions such as osteoarthritis, as well as sports and other injuries. Many wonder if we can heal muscle and joint damage using PRP and stem cell therapy, just how much more can we potentially heal?
Potential of Stem Cell Therapy Over Hip Replacement Surgery
Based on current evidence, it may be possible in the near future to consider PRP and stem cell therapy over hip replacement surgery. A 2016 study published in the Proceedings of the National Academy of Sciences showed that stem cells successfully grew on an artificial hip joint. The researchers even created a therapy that, combined with stem cells, could lower the risk of arthritis recurrence in the joint.
What Treatments Are We Already Utilizing?
While seeing hip replacements become a thing of the past is a potential occurrence in the near future, the science is not there yet. Adimarket is working to provide the tools necessary to utilize both PRP and stem cell therapy in treating sports injuries, wounds, and orthopedic applications.
In fact, the two therapies are in no way mutually exclusive. In many cases, both PRP and stem cell therapies can be utilized simultaneously, as long as the stem cells come from the patient themselves. This helps reduce the risk of rejection.
PRP can be extracted from the blood, and the stem cells can come from bone marrow or fat tissue. These are then injected directly into the treatment site, and we simply wait for the magic to happen.
Adimarket Has Got You Covered
If you are a doctor or own your practice, we urge you to consider adding PRP and stem cell therapies to your treatment options. Adimarket provides a wide range of technology and equipment designed to give patients the best experience and treatment possible.
Our equipment is some of the best in the trade. We provide fast and reliable processing of platelets, capable of concentrating blood platelets up to 16 times. If you are interested in learning more or providing this equipment in your practice, consider looking up Adimarket.
Will we ever see hip replacement surgery become obsolete? Possibly. It is our hope that it does. Until then, we aim to provide the necessary technology to help doctors offer the best stem cell and PRP treatments to their patients.
ide the necessary technology to help doctors provide the best stem cell and PRP treatment to their patients.
- Published in Corporate News / Blog
Bone and Tissue Regeneration A Game Changer
British researchers at the University of Birmingham conducted a study that could alter the field of regenerative medicine. They developed a way to regenerate human bone and tissue using nano-scale structures, helping the body more efficiently replace lost tissue. Although it will be many years before the technology is approved for public use, the implications of this research can significantly alter the use of stem cell therapy.
Advancements in Stem Cell Therapy
Global Stem Cells Group offers not only equipment and kits for point-of-care stem cell applications, but also through Stem Cells Training Inc, we provide physicians with hands-on stem cell training. This training is designed for those who want to get involved in this exciting field of medicine. Degenerative conditions could be better treated through the use of stem cell technology. To better understand what this technology entails, we will use osteoarthritis as a prime example.
Understanding Osteoarthritis and Stem Cell Therapy
In case you were unaware, osteoarthritis is a condition where the tissue between the joints starts to degrade, preventing the free movement of the joints. This can cause severe pain in sufferers of the condition. To help relieve the pain, the doctors attending our courses are taught to use the equipment for PRP and adipose-derived stem cells isolation and processing. The use of this technology can help reverse some of the effects, lower pain, and allow for more movement.
What Was Discovered in the Study
It was discovered by the researchers that these nano-structures could be produced naturally through the stimulation of human cells. These structures are known as vesicles, small extracellular structures that can have a multitude of functions, such as helping cells create certain substances.
Researchers concluded that “purifying” these vesicles could produce a substance highly beneficial in regenerative medicine. This could be used to create new growth tissue. The efforts were focused on making a tissue that can be used in more than one patient, as opposed to the more autologous method that current doctors are trained in.
Autologous vs. Allogeneic Treatments
Autologous treatment involves taking stem cells from the patient being treated and injecting them into the treatment area. This method lowers rejection rates, but each treatment requires new stem cells. The researchers at the University of Birmingham are exploring a new approach.
They aim to create a treatment that any patient can use. They believe that vesicles are important in this process and have shown that vesicles can be used to regenerate tissue regardless of the initial owner of the cells. This means that a single sample could potentially be used to treat multiple people.
Why This Matters
Regardless of the criticisms of stem cell research, ongoing research allows us to further train our doctors. This excites us as we strive to teach the best and most effective methods for our patients. This research helps us treat countless patients and makes significant strides in medical research, helping people worldwide seek treatment for various ailments.
Regenerative medicine has great potential. It can alter the landscape of modern healthcare, shifting it away from an era reliant on surgery and medications to treat every ailment. Regenerative medicine offers a promising alternative that will help treat and potentially cure diseases, rather than just managing symptoms.
Future Implications
Hopefully, this research will prove effective and be applicable to a wide range of diseases, potentially eliminating the need for various surgeries. This could also reduce the number of pharmaceuticals on the market. Over time, this treatment may help us create whole tissue in the lab.
- Published in Corporate News / Blog
Global Stem Cells Group Founder and CEO Benito Novas Recognized as a Leader in Regenerative Medicine
Image: Benito Novas
Global Stem Cells Group founder and CEO Benito Novas was recognized as a leader in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.
MIAMI, Dec. 22, 2017—Benito Novas, founder and CEO of Global Stem Cells Group (GSCG), earned recognition for his leadership in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.
Novas accepted the recognition, signed and presented to him by Congress President Rector Doctor Arturo Conde at the event, honoring him for helping thousands of physicians around the world bring regenerative medicine therapies to their clinical practices.
Novas provided training and equipment to physicians throughout South America, North America, Europe, Asia, and the Middle East through GSCG affiliate companies Stem Cell Training, Adimarket online regenerative medicine store, and Stem Cell Center Network (present in more than 30 cities globally).
Novas is a global entrepreneur, manager, and keynote speaker with expertise in the field of specialized marketing focused on biotechnology, life sciences, and healthcare development.
The philosophy that has driven him to launch and grow his companies is the desire for a perpetual flow of knowledge and innovation with regard to the role of stem cells in modern medicine.
“My aim is to accelerate the process of getting promising stem cell research and technology developed into treatments and therapies, and to make them readily available to benefit the health and well-being of a broad range of patients,” he says.
Using specialized marketing techniques focused on stem cells and their impact on the field of aesthetic surgery, Novas created a multi-company corporation based on his visionary approach to healthcare management and regenerative medicine.
To learn more about Global Stem Cells Group, visit the company website, email info@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
Benito Novas recognized
- Published in Press Releases
Adimarket, a Subsidiary of Global Stem Cells Group, to Distribute Alolotl Biologix Biological Products Worldwide
Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.
MIAMI, Dec.21, 2017— Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.
Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.
Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:
AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:
- Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
- Immune privileged with anti-inflammatory and anti-bacterial properties
- A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
- Contains extracellular matrix components for cellular attachment and proliferation
- Cryopreserved for an extended shelf life
AxoBioFluid® physician benefits
- Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy degenerated tissue is provided.
AxoBioFluid® patient benefits
Relevant Conditions
AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:
- Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
- Immune privileged with anti-inflammatory and anti-bacterial properties
- A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
- Contains extracellular matrix components for cellular attachment and proliferation
- Cryopreserved for an extended shelf life
AxoBioFluidâ physician benefits
- Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy is provided.
AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.
AxoBioFluid
- Degenerative disorders such as osteoarthritis
• Joint pain
• Inflammatory conditions such as: - Bursitis
- Tendonitis
- Fasciitis
- Epicondylitis
- Soft tissue injuries such as:
- Ligament & Tendon sprains
- Muscle & Meniscus tears
- Wound Care
AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:
- Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
- Immune privileged with anti-inflammatory and anti-bacterial properties
- Contains extracellular matrix components for cellular attachment and proliferation
- Dehydrated and terminally e-beam sterilized for an extended shelf life.
AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization. It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.
AxoBioMembraneä physician benefits
- Procedures are efficient and do not require special instrumentation.
- AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
- We provide a library of research and white papers to demonstrate efficacy.
AxoBioMembraneä patient benefits:
- Pain Reduction
- Wound Adherence
- Less Scarring
- Faster Healing
- Neovascularization
- Wound Barrier
- Anti-bacterial
- Immune Privileged
AxoBio products are available to purchase on the Adimarket Website.
For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.
Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.
About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.
Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.
About Alolotl Biologix:
Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue, medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols. For more information, visit www.axobio.com.
###
amniotic biofluid
- Published in Press Releases
